EPS for Globus Medical, Inc. (GMED) Expected At $0.36

April 26, 2018 - By Linda Rogers

Globus Medical, Inc. (NYSE:GMED) LogoInvestors sentiment decreased to 0.99 in Q4 2017. Its down 0.39, from 1.38 in 2017Q3. It dived, as 26 investors sold Globus Medical, Inc. shares while 83 reduced holdings. 40 funds opened positions while 68 raised stakes. 59.89 million shares or 7.54% less from 64.77 million shares in 2017Q3 were reported.
Loomis Sayles Co Limited Partnership has 0% invested in Globus Medical, Inc. (NYSE:GMED) for 228 shares. Ameriprise Fincl has invested 0.01% in Globus Medical, Inc. (NYSE:GMED). Friess Associate Ltd Com has invested 0.48% in Globus Medical, Inc. (NYSE:GMED). Missouri-based Argent Cap Management Lc has invested 0.15% in Globus Medical, Inc. (NYSE:GMED). Commonwealth Of Pennsylvania Pub School Empls Retrmt Systems accumulated 10,588 shares or 0.01% of the stock. Lpl Limited Liability stated it has 28,071 shares. Godshalk Welsh Cap Mgmt holds 64,892 shares or 2.7% of its portfolio. Pnc Financial Services Group Inc stated it has 0% in Globus Medical, Inc. (NYSE:GMED). Renaissance Technologies Ltd Company has invested 0.02% in Globus Medical, Inc. (NYSE:GMED). Delta Asset Mngmt Ltd Liability Corp Tn holds 0% or 39 shares in its portfolio. Blair William & Commerce Il has 0% invested in Globus Medical, Inc. (NYSE:GMED) for 12,380 shares. Meeder Asset Management reported 0% of its portfolio in Globus Medical, Inc. (NYSE:GMED). Schwab Charles Investment Mgmt Inc has 0.01% invested in Globus Medical, Inc. (NYSE:GMED). Northwestern Mutual Wealth Management stated it has 0% in Globus Medical, Inc. (NYSE:GMED). Amer Century Companies Inc invested in 768,760 shares or 0.03% of the stock.

Analysts expect Globus Medical, Inc. (NYSE:GMED) to report $0.36 EPS on May, 2.They anticipate $0.04 EPS change or 12.50 % from last quarter’s $0.32 EPS. GMED’s profit would be $34.80M giving it 36.14 P/E if the $0.36 EPS is correct. After having $0.38 EPS previously, Globus Medical, Inc.’s analysts see -5.26 % EPS growth. The stock increased 0.74% or $0.38 during the last trading session, reaching $52.04. About 682,582 shares traded or 8.84% up from the average. Globus Medical, Inc. (NYSE:GMED) has risen 65.36% since April 26, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.

Globus Medical, Inc. (NYSE:GMED) Ratings Coverage

Among 9 analysts covering Globus Medical (NYSE:GMED), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Globus Medical had 14 analyst reports since November 9, 2017 according to SRatingsIntel. Barclays Capital maintained it with “Underweight” rating and $29 target in Thursday, November 9 report. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Buy” rating by Piper Jaffray on Tuesday, January 2. Canaccord Genuity maintained the shares of GMED in report on Wednesday, November 8 with “Buy” rating. Morgan Stanley maintained it with “Overweight” rating and $53 target in Thursday, February 22 report. Canaccord Genuity maintained Globus Medical, Inc. (NYSE:GMED) rating on Thursday, February 22. Canaccord Genuity has “Buy” rating and $53.0 target. Needham upgraded Globus Medical, Inc. (NYSE:GMED) on Wednesday, April 4 to “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Thursday, January 4. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Neutral” rating by Bank of America on Friday, November 10. The rating was maintained by Leerink Swann on Wednesday, March 28 with “Buy”. The firm has “Neutral” rating given on Monday, April 16 by BTIG Research.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $5.03 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 47.31 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

Globus Medical, Inc. (NYSE:GMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: